Introduction
============

Resistance of effector T cells (Teff) to suppression contributes to disturbed immune regulation in autoimmune disease. Targeting this unresponsiveness to suppression might therefore have beneficial effects in autoimmune inflammation. In juvenile idiopathic arthritis (JIA) we have recently shown that Teff from inflamed joints are refractory to suppression, which was associated with enhanced PKB/c-akt activation in these cells.

Objectives
==========

To investigate whether anti-IL-6 and anti-TNFα target unresponsiveness of Teff to suppression in patients with JIA.

Methods
=======

Resistant Teff from the inflamed joints of JIA patients were cultured in the presence of etanercept or anti-IL-6 *in vitro*and PKB/c-akt activation and responsiveness to suppression was measured. In addition, *in vivo*effects of TNFα blockade were investigated using peripheral blood samples of patient before and after start of etanercept therapy.

Results
=======

*In vitro*treatment of synovial fluid Teff with anti-IL-6 led to improved Treg mediated suppression of cell proliferation in some, but not all patients. Blocking TNFα with etanercept however clearly enhanced suppression in all samples analyzed. In the presence of etanercept PKB/c-akt activation of Teff was reduced and Teff became more susceptible to TGFβ-mediated suppression, indicating that anti-TNFα directly targets resistant Teff.

Conclusion
==========

This study is the first to show resistance of Teff to suppression as a target of anti-TNFα therapy in arthritis, resulting in improved regulation of inflammatory effector cells.
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